NEW YORK, NY / ACCESSWIRE / August 22, 2022 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Kiromic BioPharma, Inc. KRBP

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.

A class action has commenced on behalf of certain shareholders in Kiromic BioPharma, Inc. The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the "Offering Documents") failed to disclose that the Food and Drug Administration ("FDA") had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ("IND") applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

Shareholders may find more information at https://securitiesclasslaw.com/securities/kiromic-biopharma-inc-loss-submission-form/?id=31073&from=1

Co-Diagnostics, Inc. CODX

This lawsuit is on behalf of a class of all persons and entities who purchased the publicly traded securities of Co-Dx during the period of May 12, 2022 through the close of the market on August 11, 2022 (4:00 p.m. ET).

A class action has commenced on behalf of certain shareholders in Co-Diagnostics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) demand for the Company's Logix Smart™ COVID-19 test had plummeted throughout the quarter ended June 30, 2022, and (ii) as a result, defendants' positive statements about the demand for its Logix Smart™ COVID-19 test lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/co-diagnostics-inc-loss-submission-form-2/?id=31073&from=1

MINISO Group Holding Limited MNSO

This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded MINISO securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with MINISO's October 2020 initial public offering.

A class action has commenced on behalf of certain shareholders in MINISO Group Holding Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) defendants and other undisclosed related parties owned and controlled a much larger amount of MINISO stores than previously stated; (2) as a result, MINISO concealed its true costs; (3) the Company did not represent its true business model; (4) defendants, including the Company and its chairman, engaged in planned unusual and unclear transactions; (5) as a result of at least one of these transactions, the Company is at risk of breaching contracts with People's Republic of China authorities; (6) the Company would imminently and drastically drop its franchise fees; and (7) as a result, defendant's statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/miniso-group-holding-limited-loss-submission-form/?id=31073&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE : The Gross Law Firm

View source version on accesswire.com: